Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ulrich Germing

Showing results (161-170 of 339) with videos related to

Pageof 34
Sort By:
British Journal of Haematology|April 1, 2022
Evolution of severe (transfusion-dependent) anaemia in myelodysplastic syndromes with 5q deletion is characterized by a macrophage-associated failure of the eythropoietic nicheGuntram Buesche, Huesniye Teoman, Rebekka K Schneider, et al.
The Lancet. Oncology|September 6, 2017
Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension studyUwe Platzbecker, Ulrich Germing, Katharina S Götze, et al.
Annals of Hematology|June 27, 2025
Non-curative therapies and their impact on the prognosis of patients with myelodysplastic syndromes- a retrospective matched-pairs analysisKatharina Anna Rauhe, Annika Kasprzak, Felicitas Schulz, et al.
International Journal of Cancer|May 13, 2016
Expression of CDKN1C in the bone marrow of patients with myelodysplastic syndrome and secondary acute myeloid leukemia is associated with poor survival after conventional chemotherapyAleksandar Radujkovic, Sascha Dietrich, Mindaugas Andrulis, et al.
Leukemia & Lymphoma|September 16, 2017
Myelodysplastic syndromes (MDS) in regular care in Germany - the oldest patients come to the foreHans Tilman Steinmetz, Ulrich Germing, Annette Sauer, et al.
Annals of Hematology|April 12, 2026
Influence of different therapy strategies in patients with myelodysplastic neoplasms (MDS) on overall survival with regard to different decades: data from the German MDS registryJonas Welsch, Felicitas Schulz, Annika Kasprzak, et al.
Annals of Hematology|August 12, 2016
Selective expansion of regulatory T cells during lenalidomide treatment of myelodysplastic syndrome with isolated deletion 5qEkaterina Balaian, Claudia Schuster, Claudia Schönefeldt, et al.
Annals of Hematology|November 22, 2014
Calreticulin mutations are not present in patients with myeloproliferative chronic myelomonocytic leukemiaLurdes Zamora, Ulrich Germing, Marta Cabezón, et al.
International Journal of Molecular Sciences|February 15, 2019
Clonal Hematopoiesis with Oncogenic Potential (CHOP): Separation from CHIP and Roads to AMLPeter Valent, Wolfgang Kern, Gregor Hoermann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2007
Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromesLuca Malcovati, Ulrich Germing, Andrea Kuendgen, et al.
Pageof 34

Showing results (161-170 of 339) with videos related to

Sort By:
Pageof 34
British Journal of Haematology|April 1, 2022
Evolution of severe (transfusion-dependent) anaemia in myelodysplastic syndromes with 5q deletion is characterized by a macrophage-associated failure of the eythropoietic nicheGuntram Buesche, Huesniye Teoman, Rebekka K Schneider, et al.
The Lancet. Oncology|September 6, 2017
Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension studyUwe Platzbecker, Ulrich Germing, Katharina S Götze, et al.
Annals of Hematology|June 27, 2025
Non-curative therapies and their impact on the prognosis of patients with myelodysplastic syndromes- a retrospective matched-pairs analysisKatharina Anna Rauhe, Annika Kasprzak, Felicitas Schulz, et al.
International Journal of Cancer|May 13, 2016
Expression of CDKN1C in the bone marrow of patients with myelodysplastic syndrome and secondary acute myeloid leukemia is associated with poor survival after conventional chemotherapyAleksandar Radujkovic, Sascha Dietrich, Mindaugas Andrulis, et al.
Leukemia & Lymphoma|September 16, 2017
Myelodysplastic syndromes (MDS) in regular care in Germany - the oldest patients come to the foreHans Tilman Steinmetz, Ulrich Germing, Annette Sauer, et al.
Annals of Hematology|April 12, 2026
Influence of different therapy strategies in patients with myelodysplastic neoplasms (MDS) on overall survival with regard to different decades: data from the German MDS registryJonas Welsch, Felicitas Schulz, Annika Kasprzak, et al.
Annals of Hematology|August 12, 2016
Selective expansion of regulatory T cells during lenalidomide treatment of myelodysplastic syndrome with isolated deletion 5qEkaterina Balaian, Claudia Schuster, Claudia Schönefeldt, et al.
Annals of Hematology|November 22, 2014
Calreticulin mutations are not present in patients with myeloproliferative chronic myelomonocytic leukemiaLurdes Zamora, Ulrich Germing, Marta Cabezón, et al.
International Journal of Molecular Sciences|February 15, 2019
Clonal Hematopoiesis with Oncogenic Potential (CHOP): Separation from CHIP and Roads to AMLPeter Valent, Wolfgang Kern, Gregor Hoermann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2007
Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromesLuca Malcovati, Ulrich Germing, Andrea Kuendgen, et al.
Pageof 34